Paper Details

  1. Home
  2. Paper Details

Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination.

Author: LiuChen, LunaAesis, PhamKien, StudzinskiGeorge P, WangXuening, WuQunfeng

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study investigated the combination of Doxercalciferol (D2), a vitamin D2 analog, with carnosic acid (CA) and sorafenib (Sf) for treating hepatocellular carcinoma (HCC). The combination increased HCC cell death, enhancing autophagy and apoptosis.
Paper Details　
Original Abstract of the Article :
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and it is the third leading cause of global cancer mortality. Sorafenib (Sf) is the first oral multi-kinase inhibitor approved for systemic treatment of advanced HCC, and can prolong survival, although only for three months longe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/31704246

データ提供：米国国立医学図書館（NLM）

A Promising Trio: Sorafenib, Carnosic Acid, and Vitamin D2 Analog for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC), a type of liver cancer, is a significant health concern. This research explores a novel therapeutic approach combining Sorafenib, an existing HCC treatment, with Carnosic Acid and a Vitamin D2 analog. The researchers tested this combination on HCC cell lines, finding that it effectively increased cell death and enhanced both autophagy and apoptosis. It's like a trio of powerful desert plants working together to overcome a stubborn sandstorm! The study highlights the potential of this combination therapy to improve HCC treatment outcomes.

A Collaborative Approach to HCC Treatment

The study suggests that combining Sorafenib with Carnosic Acid and a Vitamin D2 analog could be a promising approach for HCC treatment. This synergistic combination, like the interconnectedness of a desert ecosystem, could enhance the efficacy of existing therapies.

A Potential Boost for HCC Treatment: A Trio of Hope

This research offers a glimmer of hope in the fight against HCC. The study's findings suggest that this combination therapy could offer a more effective approach to treating this challenging disease. It's like discovering a hidden oasis of therapeutic possibilities within the vast desert of cancer research.

Dr. Camel's Conclusion

The study presents a compelling case for the potential of combining Sorafenib, Carnosic Acid, and a Vitamin D2 analog to combat HCC. This research highlights the importance of exploring synergistic treatment approaches and emphasizes the potential of utilizing natural compounds alongside traditional therapies.

Date :
  1. Date Completed 2020-07-06
  2. Date Revised 2021-09-19
Further Info :

Pubmed ID

31704246

DOI: Digital Object Identifier

NIHMS1545338

Related Literature

Article Analysis
・Effects of doxercalciferol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.